Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07285720
Recruiting Not applicable

Phonological Constraints on Language Development in Individuals With Williams Syndrome

NCT07285720 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire, Amiens
Phase
Not applicable
Started
2024-07-05
Last updated
2025-12-16

Condition(s) studied

Williams SyndromeLanguagePhonological Short-Term MemoryEEG-NIRS

Investigational drug(s) / intervention(s)

EEG-NIRS protocolQuestionnaire

EEG-NIRS protocol: Each participant will be tested individually in a quiet room at the GRAMFC (Groupe de Recherches sur l'Analyse Multimodale de la Fonction Cérébrale, INSERM-UMR1105, Université Picardie Jules Verne and CHU Amiens-Picardie). Duration of subject's participation in the study is 120 minutes

Questionnaire: Each participant will be tested individually in a quiet room at the GRAMFC (Groupe de Recherches sur l'Analyse Multimodale de la Fonction Cérébrale, INSERM-UMR1105, Université Picardie Jules Verne and CHU Amiens-Picardie). Duration of subject's participation in the study is 120 minutes

Study summary

Williams syndrome (WS) is a neurodevelopmental disease characterized by mild to moderate intellectual disability and an extremely heterogeneous cognitive profile. Research has outlined two main features of WS: an atypical social behavior associated with surprising language abilities, and a hyperacusis. The purpose of this project is to investigate the relationships between both these abilities, and particularly the role of the hyperacusis on language abilities. The hyperacusis would be crucial in developing language skills: the apparent strength in the verbal domain could rely on Phonological Short Term Memory (PSTM) more in individuals with WS than in typically developing individuals. In addition, the investigators will compare individuals with WS to individuals with Down syndrome (DS): DS is often associated to strong limitations in the PSTM with poor language abilities. To this end, the investigators will use a highly innovative approach including physiological assessments (EEG-NIRS protocol) and questionnaires. The performance of people with WS will be compared to those of participants with DS and TD participants of same DA and cognitive assessments.

Eligibility

Sex
ALL
Min age
6 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * For SW and SD: genetic diagnosis and aged between 6- and 17 years old. * For typical participants: any child, adolescent or young adult of the same developmental or chronological age (between 6 and 17 years of age) * adult group (between 20 and 60 years). Exclusion Criteria: * Autistic Associated Disorders, * West syndrome

Primary outcome measure(s)

  • questionnaire score of patients with WS caracterisation — 2 years
    questionnaire score for cognitive profile of patients with WS caracterisation

Trial sites (1)

FacilityCityRegionStatus
CHU Amiens Amiens France Recruiting

More Centre Hospitalier Universitaire, Amiens trials in France

The Clinical and Hemodynamic Course of Cardiogenic Shocks Hospitalized in Critical Care Recruiting
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection Recruiting
Induced Membrane Properties in Children and Adults Recruiting
Place of Nasogastric Tube in Uncomplicated Adhesive Small Bowel Obstruction Recruiting
Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07285720 on ClinicalTrials.gov ↗ ← All trials in France